Hub : Traits :

Smoking Status

742 significantly associated models · 197 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	7715776	9571422	2	1	3.5e-10	1.4e-08	9.2e-01	100	RERE
2	1	31494475	32929175	1	1	4.9e-08	1.8e-08	1.0e+00	100	BAI2
3	1	33030461	34592020	2	1	3.8e-09	2.9e-09	1.0e+00	100	PHC2
4	1	43152610	45109101	3	1	8.2e-10	1.4e-13	3.2e-06	60	ST3GAL3
5	1	48301764	51180660	1	1	2.6e-08	1.9e-11	4.9e-05	63	AGBL4
6	1	66019891	67086881	1	1	6.2e-11	4.5e-11	2.2e-02	88	PDE4B
7	1	153496711	154944156	2	1	7.2e-12	1.3e-11	5.6e-03	83	HAX1
8	2	43417083	45864710	2	2	5.1e-19	8.5e-19	1.0e+00	100	LRPPRC RP11-89K21.1
9	2	47224927	48727280	1	1	2.2e-07	4.3e-06	8.5e-01	100	MSH6
10	2	161297929	162790882	1	1	3.1e-09	7.0e-09	4.9e-03	76	TANK
11	2	200553557	201060216	1	1	1.6e-07	1.3e-07	1.0e+00	100	C2orf60
12	3	24941038	26396178	1	1	1.8e-08	1.4e-08	1.0e-08	-2	TOP2B
13	3	48012797	51043528	26	2	1.9e-11	2.8e-09	5.5e-02	90	HYAL3 RHOA
14	3	51616334	53778875	12	1	1.2e-08	3.3e-09	1.0e+00	100	PPM1M
15	3	84317575	86808226	1	1	4.4e-20	4.7e-18	7.5e-01	100	CADM2
16	5	59353199	61145102	3	1	1.5e-09	9.3e-10	4.7e-02	90	ELOVL7
17	5	86867897	88427942	1	1	6.1e-08	1.7e-09	7.9e-03	81	TMEM161B-AS1
18	5	169590807	171533656	2	1	3.6e-08	9.7e-09	1.0e+00	100	NPM1
19	6	36751245	38162310	2	1	3.6e-08	4.4e-09	7.2e-03	79	C6orf129
20	6	110588546	112621834	5	1	1.9e-19	2.1e-20	8.0e-03	92	GTF3C6
21	7	1181139	2580275	2	2	2.6e-09	5.2e-10	2.8e-01	97	AC110781.3 KIAA1908
22	7	2646223	5003373	1	1	8.2e-09	1.6e-11	3.8e-06	53	SDK1
23	7	96405380	96896364	1	1	3.0e-08	5.9e-12	6.9e-06	57	DLX5
24	7	98244565	99751521	3	1	1.7e-09	6.2e-09	4.2e-01	98	CPSF4
25	7	109603832	111895681	1	1	2.2e-07	1.6e-07	1.0e+00	100	IMMP2L
26	7	116660803	118518479	2	2	7.9e-14	5.0e-14	1.0e+00	100	CTTNBP2 NAA38
27	8	26648746	28100234	2	2	6.0e-20	9.9e-24	1.9e-04	86	CLU EPHX2
28	8	65812899	67199420	1	1	1.9e-07	4.4e-07	3.3e-02	82	CTD-3025N20.3
29	8	91282507	92689456	1	1	3.3e-08	1.9e-10	9.9e-04	73	RP11-122A3.2
30	9	126927285	129422783	9	6	6.1e-15	1.1e-13	NaN	NaN	ARPC5L GAPVD1 MAPKAP1 PPP6C
31	10	10349662	12076043	1	1	2.7e-09	2.8e-07	5.8e-02	86	CELF2
32	10	21087485	22724472	2	1	3.8e-08	4.3e-08	2.4e-01	95	CASC10
33	10	102864652	105910221	20	9	1.1e-22	1.3e-22	NaN	NaN	ACTR1A AS3MT BTRC C10orf32 NT5C2 RP11-18I14.10 WBP1L
34	11	16343081	18106069	3	1	1.3e-09	3.1e-10	7.8e-03	82	PIK3C2A
35	11	26818083	28416646	2	2	1.8e-07	2.0e-15	8.4e-10	40	BDNF-AS LIN7C
36	11	63417724	65186348	2	2	1.6e-07	6.0e-07	3.7e-01	97	CCDC88B NRXN2
37	11	112135760	113846006	2	1	6.7e-14	3.6e-43	7.9e-32	27	NCAM1
38	11	133540722	134074099	1	1	7.9e-08	8.3e-08	1.0e+00	100	IGSF9B
39	12	55444736	57125879	5	1	6.8e-09	6.8e-08	8.8e-02	90	SUOX
40	12	108342014	109820777	1	1	1.1e-07	2.4e-07	1.8e-01	93	CORO1C
41	12	119870094	122037099	7	3	7.7e-10	3.1e-09	7.4e-01	100	C12orf43 COQ5 UNC119B
42	14	103289637	105211221	5	7	1.2e-09	2.5e-09	NaN	NaN	KLC1 PPP1R13B TDRD9 XRCC3
43	15	46780520	48764942	1	1	8.1e-13	3.8e-17	1.4e-09	48	SEMA6D
44	15	67138238	68789191	1	1	1.7e-07	3.4e-07	1.0e-02	74	MAP2K5
45	15	90730363	92135418	1	1	2.3e-07	7.1e-06	3.2e-01	95	FES
46	16	86671	1488646	13	1	1.5e-11	2.7e-11	1.8e-01	96	WDR24
47	16	30347731	31720486	1	1	4.5e-08	2.1e-07	6.9e-05	41	STX1B
48	16	69062879	70725815	5	2	1.4e-10	4.8e-11	2.0e-01	96	NOB1 PDXDC2P
49	16	89339571	89871168	1	1	1.4e-07	6.9e-07	8.3e-02	88	SPG7
50	17	1263564	2923933	2	1	1.1e-10	1.3e-09	3.9e-02	88	SRR
51	17	7577407	8066783	1	1	8.4e-08	2.3e-08	4.0e-02	86	KCNAB3
52	17	37137299	38547868	2	1	8.4e-08	8.2e-08	4.7e-02	86	PGAP3
53	17	44788310	45088455	1	1	3.0e-07	1.0e-04	2.8e-01	92	LRRC37A2
54	18	69836	907710	1	1	5.7e-08	9.5e-09	3.5e-02	87	USP14
55	20	30591354	32029439	1	1	1.7e-08	1.2e-10	7.2e-05	62	COMMD7
56	20	61576647	62912463	2	1	8.6e-08	9.5e-06	1.0e-01	86	RTEL1
57	21	46440385	46956571	1	1	1.7e-07	3.1e-07	3.0e-01	96	POFUT2
58	22	41181586	43674249	11	3	5.1e-11	4.0e-10	2.9e-03	77	CYP2D8P1 DESI1 RRP7B
59	22	45736153	47135205	2	1	1.6e-08	3.3e-08	8.5e-02	90	LINC00899

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Past tobacco smoking	10.65	48	18	40.0	-0.99	5.1e-42	AC110781.3 ACTR1A AS3MT C10orf32 C6orf129 CADM2 CASC10 CELF2 CLU COMMD7 CPSF4 CTD-3025N20.3 CTTNBP2 DLX5 ELOVL7 EPHX2 GAPVD1 GTF3C6 HAX1 HYAL3 KIAA1908 LIN7C LRPPRC MAP2K5 MSH6 NCAM1 NOB1 NPM1 NRXN2 NT5C2 PDE4B PDXDC2P PGAP3 PHC2 PPM1M PPP6C RP11-89K21.1 SDK1 SPG7 SRR STX1B SUOX TANK TDRD9 TMEM161B-AS1 TOP2B WBP1L WDR24
Ever smoked	9.72	34	15	33.3	0.99	2.0e-32	AC110781.3 ACTR1A AS3MT C10orf32 C2orf60 CADM2 COMMD7 CPSF4 CTTNBP2 ELOVL7 GAPVD1 GTF3C6 HYAL3 KIAA1908 LINC00899 MAP2K5 MSH6 NCAM1 NOB1 NRXN2 NT5C2 PDE4B PDXDC2P PGAP3 PHC2 PPP6C RP11-89K21.1 SDK1 SRR STX1B TMEM161B-AS1 TOP2B WBP1L WDR24
Smoking status: Current	8.76	30	9	20.0	0.99	1.8e-27	ACTR1A AGBL4 ARPC5L AS3MT C10orf32 C12orf43 CLU COQ5 CORO1C CTTNBP2 CYP2D8P1 DESI1 EPHX2 GAPVD1 GTF3C6 KLC1 MAPKAP1 NT5C2 PIK3C2A PPP1R13B PPP6C RHOA RP11-89K21.1 RRP7B RTEL1 SEMA6D SRR ST3GAL3 TDRD9 XRCC3
Current tobacco smoking	8.52	26	9	20.0	0.98	1.2e-23	ACTR1A ARPC5L AS3MT C10orf32 C12orf43 CLU COQ5 CTTNBP2 DESI1 EPHX2 GAPVD1 GTF3C6 KLC1 MAPKAP1 PIK3C2A PPP1R13B PPP6C RERE RHOA RRP7B RTEL1 SEMA6D ST3GAL3 TDRD9 WBP1L XRCC3
Smoking status: Previous	6.61	16	3	6.7	0.98	7.3e-11	ACTR1A C10orf32 CADM2 CASC10 COMMD7 GTF3C6 HYAL3 KIAA1908 MSH6 NCAM1 NOB1 PHC2 RP11-89K21.1 SDK1 STX1B WBP1L
Maternal smoking around birth	4.75	7	2	4.4	0.99	7.0e-07	ACTR1A AS3MT C10orf32 CASC10 PPP1R13B TDRD9 XRCC3
Schizophrenia (2018)	4.23	13	8	17.8	0.04	8.7e-01	ACTR1A AS3MT C10orf32 FES IMMP2L KLC1 NT5C2 PPM1M PPP1R13B RERE ST3GAL3 TDRD9 XRCC3
Schizophrenia (2014)	4.18	17	9	20.0	0.14	5.4e-01	AC110781.3 ACTR1A AS3MT C10orf32 CLU FES IMMP2L KLC1 NT5C2 PIK3C2A PPM1M PPP1R13B RERE SPG7 ST3GAL3 TDRD9 XRCC3
Bipolar Disorder or Schizophrenia	3.91	14	11	24.4	0.13	6.1e-01	ACTR1A AS3MT C10orf32 FES IMMP2L KLC1 NT5C2 PGAP3 PPM1M PPP1R13B SPG7 ST3GAL3 TDRD9 XRCC3
Risk taking	3.70	7	2	4.4	0.97	8.3e-05	CADM2 KLC1 LINC00899 PPP1R13B RP11-89K21.1 TDRD9 XRCC3
Worry (Nagel 2018)	3.57	13	7	15.6	-0.62	1.0e-02	ACTR1A AGBL4 AS3MT BTRC C10orf32 CADM2 CASC10 GAPVD1 LRRC37A2 MAP2K5 NT5C2 PPM1M TMEM161B-AS1
Worrier / anxious feelings	3.47	8	5	11.1	-0.95	1.7e-05	ACTR1A AS3MT C10orf32 CADM2 LRRC37A2 NOB1 NT5C2 TMEM161B-AS1
Qualifications: College or University degree	3.47	18	11	24.4	-0.88	1.6e-06	ACTR1A BAI2 CADM2 CASC10 CELF2 CTTNBP2 ELOVL7 HYAL3 LRRC37A2 RHOA RRP7B RTEL1 SDK1 SEMA6D ST3GAL3 SUOX TANK WDR24
Nervous feelings	3.44	11	5	11.1	-0.95	5.5e-07	ACTR1A AGBL4 AS3MT C10orf32 CADM2 LRRC37A2 MAP2K5 NT5C2 PPM1M SRR TMEM161B-AS1
Townsend deprivation index at recruitment	3.39	1	0	0.0	0.00	1.0e+00	CTTNBP2
BMI	3.20	29	21	46.7	0.86	2.3e-10	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS C2orf60 CADM2 CASC10 CPSF4 GTF3C6 HYAL3 KLC1 LIN7C MAP2K5 NOB1 NPM1 NRXN2 PDE4B PHC2 POFUT2 PPM1M PPP1R13B RHOA RTEL1 SRR STX1B SUOX TDRD9 XRCC3
Body mass index (BMI)	3.17	25	13	28.9	0.95	2.5e-14	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS C2orf60 CADM2 CASC10 CPSF4 HYAL3 KLC1 LIN7C MAP2K5 NOB1 NPM1 PDE4B PHC2 PPM1M PPP1R13B RERE RHOA STX1B SUOX TDRD9 XRCC3
Pack years adult smoking proportion	3.14	5	1	2.2	0.98	2.3e-03	AGBL4 KLC1 PPP1R13B SEMA6D XRCC3
Leg fat mass (right)	3.10	19	13	28.9	0.94	1.2e-09	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS CADM2 CASC10 CPSF4 GTF3C6 LIN7C MAP2K5 NPM1 PDE4B PHC2 RERE RHOA RTEL1 SPG7 STX1B
Leg fat mass (left)	3.10	19	13	28.9	0.94	1.0e-09	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS CADM2 CASC10 CPSF4 GTF3C6 LIN7C MAP2K5 NPM1 PDE4B PHC2 RERE RHOA RTEL1 SPG7 STX1B
Systolic Blood Pressure	3.03	18	10	22.2	-0.62	2.6e-03	AC110781.3 ACTR1A AS3MT BTRC C2orf60 CADM2 COQ5 FES GAPVD1 LIN7C MAPKAP1 NT5C2 PDXDC2P PIK3C2A RERE RP11-122A3.2 SPG7 SRR
Financial difficulties in last 2 years	2.99	3	0	0.0	1.00	4.4e-03	KLC1 PPP1R13B XRCC3
Mouth/teeth dental problems	2.96	6	1	2.2	-0.84	9.7e-03	EPHX2 KLC1 LRRC37A2 PPP1R13B TDRD9 XRCC3
Pack years of smoking	2.94	3	0	0.0	0.00	1.0e+00	AGBL4 KLC1 XRCC3
Qualifications: None of the above	2.93	11	5	11.1	0.97	5.5e-07	ACTR1A BAI2 CELF2 ELOVL7 HYAL3 RHOA SEMA6D ST3GAL3 SUOX TANK WDR24
Neuroticism	2.85	10	4	8.9	-0.30	3.6e-01	AS3MT CADM2 CTTNBP2 GAPVD1 LRRC37A2 MAP2K5 NT5C2 RERE RP11-122A3.2 TMEM161B-AS1
Waist circumference	2.83	16	11	24.4	0.94	8.9e-08	AGBL4 AS3MT BAI2 BDNF-AS C2orf60 CADM2 CASC10 CPSF4 KLC1 LIN7C MAP2K5 NPM1 PDE4B PHC2 SPG7 STX1B
Alcohol usually taken with meals	2.82	3	0	0.0	0.00	1.0e+00	ACTR1A CLU CTTNBP2
Arm fat mass (left)	2.82	23	11	24.4	0.85	2.7e-07	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS C2orf60 CADM2 CASC10 CPSF4 KLC1 LIN7C MAP2K5 NOB1 NPM1 PDE4B PHC2 RERE RHOA SEMA6D SPG7 STX1B TDRD9 XRCC3
Arm fat mass (right)	2.80	24	11	24.4	0.80	3.0e-06	AGBL4 AS3MT BAI2 BDNF-AS CADM2 CASC10 CPSF4 KLC1 LIN7C MAP2K5 NOB1 NPM1 PDE4B PHC2 PPP1R13B RERE RHOA SEMA6D SPG7 SRR STX1B SUOX TDRD9 XRCC3
Leg fat percentage (left)	2.80	18	9	20.0	0.93	1.3e-08	AGBL4 BAI2 BDNF-AS CADM2 CASC10 CPSF4 GTF3C6 LIN7C MAP2K5 MAPKAP1 NPM1 PDE4B RERE RHOA RTEL1 STX1B TDRD9 WDR24
Arm fat percentage (right)	2.78	22	12	26.7	0.74	3.2e-05	AGBL4 AS3MT BAI2 BDNF-AS BTRC CASC10 CPSF4 KLC1 LIN7C MAP2K5 NOB1 NPM1 PDE4B PPP1R13B RERE RHOA SEMA6D SPG7 SRR STX1B TDRD9 XRCC3
Qualifications: A levels/AS levels or equivalent	2.76	10	4	8.9	-0.98	3.2e-07	ACTR1A BAI2 CELF2 ELOVL7 RHOA RRP7B ST3GAL3 SUOX TANK WDR24
Leg fat percentage (right)	2.75	18	9	20.0	0.92	1.6e-08	AGBL4 BAI2 BDNF-AS CADM2 CASC10 CPSF4 GTF3C6 LIN7C MAP2K5 MAPKAP1 NPM1 PDE4B RERE RHOA RP11-122A3.2 RTEL1 STX1B WDR24
Exposure to tobacco smoke outside home	2.71	4	0	0.0	0.97	3.5e-02	ACTR1A CTTNBP2 ELOVL7 LIN7C
Whole body fat mass	2.69	18	12	26.7	0.93	9.5e-09	AGBL4 AS3MT BAI2 BDNF-AS CADM2 CASC10 CPSF4 GTF3C6 LIN7C MAP2K5 NPM1 PDE4B PHC2 RERE RHOA RTEL1 SPG7 STX1B
Arm fat percentage (left)	2.68	20	10	22.2	0.71	2.1e-04	AGBL4 AS3MT BAI2 BDNF-AS BTRC CASC10 CPSF4 KLC1 LIN7C MAP2K5 NOB1 NPM1 PDE4B RERE RHOA SEMA6D SRR STX1B TDRD9 XRCC3
Respiratory disease	2.66	4	3	6.7	-0.25	7.5e-01	MAP2K5 PGAP3 RERE SUOX
Neuroticism (Nagel 2018)	2.62	11	2	4.4	-0.22	5.1e-01	AS3MT CELF2 CTTNBP2 GAPVD1 LRRC37A2 MAP2K5 NT5C2 PPM1M RERE RP11-122A3.2 TMEM161B-AS1
Long-standing illness, disability or infirmity	2.59	2	0	0.0	0.00	1.0e+00	KLC1 XRCC3
Systolic blood pressure, automated reading	2.53	8	5	11.1	-0.72	2.8e-02	AS3MT FES GAPVD1 MAPKAP1 NT5C2 PDXDC2P RERE SRR
Hip circumference	2.53	18	10	22.2	0.76	9.7e-05	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS C10orf32 CADM2 CASC10 CPSF4 GAPVD1 LIN7C MAP2K5 NPM1 NRXN2 PDE4B PHC2 RTEL1 STX1B
Body fat percentage	2.52	17	9	20.0	0.85	1.9e-05	AGBL4 BAI2 BDNF-AS BTRC CASC10 CPSF4 GTF3C6 LIN7C LRRC37A2 MAP2K5 NPM1 PDE4B RERE RTEL1 SRR STX1B TDRD9
Hand grip strength (left)	2.51	11	5	11.1	0.35	2.6e-01	ACTR1A ARPC5L AS3MT BTRC C10orf32 CADM2 GAPVD1 LRRC37A2 MAPKAP1 NOB1 PHC2
Wheeze or whistling in the chest in last year	2.50	6	2	4.4	0.98	5.2e-04	BAI2 BDNF-AS LIN7C PGAP3 RERE RTEL1
Pain experienced in last month	2.50	7	1	2.2	-0.94	1.5e-03	ARPC5L COMMD7 GAPVD1 NPM1 PPP6C RHOA SUOX
Sensitivity / hurt feelings	2.49	2	1	2.2	0.00	1.0e+00	GAPVD1 LRRC37A2
Alcohol intake versus 10 years previously	2.47	3	2	4.4	0.00	1.0e+00	CLU EPHX2 UNC119B
Weight	2.46	20	12	26.7	0.86	3.6e-07	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 CASC10 CPSF4 GAPVD1 LIN7C MAP2K5 NPM1 NT5C2 PDE4B PHC2 SPG7 STX1B SUOX
Age when periods started (menarche)	2.44	8	4	8.9	-0.32	4.0e-01	BDNF-AS GAPVD1 MAP2K5 MSH6 NOB1 PPP6C ST3GAL3 SUOX
Overall health rating	2.44	7	1	2.2	0.99	6.3e-06	AC110781.3 ARPC5L DLX5 MAPKAP1 SUOX TANK XRCC3
Hearing difficulty/problems with background noise	2.42	4	1	2.2	0.99	1.9e-03	KLC1 RP11-18I14.10 WBP1L XRCC3
Trunk fat mass	2.39	17	10	22.2	0.93	1.6e-08	AGBL4 AS3MT BAI2 BDNF-AS CADM2 CASC10 CPSF4 LIN7C LRRC37A2 MAP2K5 NPM1 PDE4B PHC2 RERE RTEL1 SPG7 STX1B
Vascular/heart problems diagnosed by doctor	2.38	7	1	2.2	-0.13	7.5e-01	FES MAP2K5 RERE RP11-18I14.10 SRR SUOX XRCC3
Blood White Count	2.36	21	11	24.4	0.59	1.8e-03	ACTR1A AS3MT C10orf32 CPSF4 FES KCNAB3 KLC1 NT5C2 PDE4B PGAP3 PPP1R13B RERE RHOA RP11-18I14.10 RTEL1 SEMA6D SRR TDRD9 TMEM161B-AS1 WBP1L XRCC3
Seen doctor (GP) for nerves, anxiety, tension or depression	2.36	2	0	0.0	0.00	1.0e+00	CTTNBP2 LINC00899
Intelligence (Savage-Jansen 2018)	2.34	10	3	6.7	-0.38	2.7e-01	ACTR1A CTD-3025N20.3 LRRC37A2 PPM1M RHOA ST3GAL3 SUOX TANK UNC119B XRCC3
Allergy	2.34	6	5	11.1	-0.24	6.4e-01	PGAP3 RERE RTEL1 SUOX UNC119B WBP1L
Qualifications: nursing, teaching	2.30	1	0	0.0	0.00	1.0e+00	CADM2
Hypertension (Self-reported)	2.29	7	1	2.2	-0.16	7.2e-01	FES MAPKAP1 PDXDC2P RERE RP11-18I14.10 SRR SUOX
High blood pressure	2.28	8	1	2.2	-0.10	8.1e-01	FES MAP2K5 MAPKAP1 PDXDC2P RERE RP11-18I14.10 SRR SUOX
Ulcerative Colitis	2.27	4	2	4.4	0.44	5.6e-01	COMMD7 PGAP3 RHOA RTEL1
Neuroticism score	2.27	4	1	2.2	-0.12	8.8e-01	CELF2 CTTNBP2 LRRC37A2 RERE
Arm predicted mass (right)	2.27	17	13	28.9	0.74	3.0e-04	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 CASC10 GAPVD1 IMMP2L LIN7C NT5C2 PHC2 SPG7 STX1B SUOX
Mouth/teeth dental problems: Dentures	2.26	4	0	0.0	1.00	2.3e-03	EPHX2 PGAP3 PIK3C2A RHOA
Depressed Affect (Nagel 2018)	2.25	6	2	4.4	0.21	6.9e-01	CELF2 LRRC37A2 RERE RHOA RP11-122A3.2 TANK
Allergy or Eczema	2.25	7	5	11.1	-0.08	8.7e-01	PGAP3 RERE RP11-18I14.10 RTEL1 SUOX UNC119B WBP1L
Average weekly beer plus cider intake	2.25	2	0	0.0	0.00	1.0e+00	BDNF-AS RP11-89K21.1
Diastolic blood pressure, automated reading	2.25	8	3	6.7	0.07	8.6e-01	CASC10 FES MAP2K5 MAPKAP1 RERE RTEL1 SRR TDRD9
Cardiovascular Disease	2.24	11	2	4.4	0.24	4.2e-01	AS3MT CCDC88B FES KLC1 MAP2K5 MAPKAP1 PPP1R13B RERE SUOX TDRD9 XRCC3
Trunk fat percentage	2.24	15	10	22.2	0.84	1.0e-04	AGBL4 BAI2 BDNF-AS BTRC CASC10 CPSF4 GTF3C6 LIN7C LRRC37A2 MAP2K5 NPM1 PDE4B RERE RTEL1 SRR
Frequency of tiredness / lethargy in last 2 weeks	2.24	3	0	0.0	0.00	1.0e+00	LIN7C RERE XRCC3
Arm fat-free mass (right)	2.24	18	11	24.4	0.69	8.6e-04	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 CASC10 GAPVD1 IMMP2L LIN7C NT5C2 PHC2 SPG7 STX1B SUOX
Medication: Paracetamol	2.23	2	1	2.2	0.00	1.0e+00	CASC10 LRRC37A2
Asthma (self-reported)	2.23	4	3	6.7	-0.27	7.3e-01	MAP2K5 PGAP3 RERE SUOX
Fluid intelligence score	2.22	5	2	4.4	-0.99	4.5e-04	CELF2 PIK3C2A ST3GAL3 TANK TOP2B
Tanning	2.21	7	3	6.7	0.66	7.5e-02	AS3MT CADM2 COMMD7 KIAA1908 MAPKAP1 PDE4B SPG7
Birth weight of first child	2.21	4	3	6.7	0.56	2.5e-01	AS3MT FES NT5C2 SUOX
Arm fat-free mass (left)	2.21	17	12	26.7	0.68	1.3e-03	ACTR1A AGBL4 AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 CASC10 DESI1 GAPVD1 LIN7C NT5C2 PHC2 SPG7 STX1B SUOX
Impedance of whole body	2.21	15	13	28.9	-0.62	9.8e-03	ACTR1A AS3MT BDNF-AS C2orf60 CADM2 CPSF4 GAPVD1 HYAL3 LIN7C LRRC37A2 PHC2 PIK3C2A PPM1M RHOA SUOX
Arm predicted mass (left)	2.21	17	11	24.4	0.68	1.4e-03	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 CASC10 GAPVD1 LIN7C NT5C2 PHC2 SPG7 STX1B SUOX
Verbal and Numeric Reasoning (VNR)	2.19	5	1	2.2	-0.66	2.3e-01	DLX5 PPM1M ST3GAL3 SUOX TANK
Leg fat-free mass (left)	2.18	20	10	22.2	0.63	1.2e-03	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 GAPVD1 LIN7C MAP2K5 NPM1 NT5C2 PDE4B PHC2 SPG7 STX1B SUOX WDR24
Leg predicted mass (left)	2.18	19	10	22.2	0.62	2.1e-03	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 GAPVD1 LIN7C MAP2K5 NPM1 NT5C2 PHC2 SPG7 STX1B SUOX WDR24
Asthma	2.18	4	3	6.7	-0.26	7.4e-01	MAP2K5 PGAP3 RERE SUOX
Number of full brothers	2.18	1	0	0.0	0.00	1.0e+00	LRRC37A2
Basal metabolic rate	2.17	20	12	26.7	0.64	9.3e-04	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 CASC10 DESI1 GAPVD1 LIN7C MAP2K5 NT5C2 PDE4B PHC2 SPG7 STX1B SUOX
Prostate Cancer	2.16	1	0	0.0	0.00	1.0e+00	WBP1L
Heel T-Score	2.16	14	10	22.2	0.24	3.6e-01	AS3MT BDNF-AS CCDC88B HYAL3 KLC1 LINC00899 LRRC37A2 MSH6 NCAM1 PPP1R13B RERE SRR TDRD9 XRCC3
Suffer from 'nerves'	2.15	4	1	2.2	-0.99	7.1e-03	AS3MT CADM2 LRRC37A2 RERE
Impedance of arm (left)	2.14	19	10	22.2	-0.72	5.7e-04	ACTR1A AGBL4 AS3MT BDNF-AS C2orf60 CADM2 CASC10 CPSF4 GAPVD1 HYAL3 KCNAB3 LIN7C LRRC37A2 PHC2 PIK3C2A PPM1M RHOA SUOX USP14
Relative age of first facial hair	2.13	3	1	2.2	0.00	1.0e+00	HYAL3 LRRC37A2 RRP7B
Impedance of arm (right)	2.13	17	13	28.9	-0.53	2.3e-02	ACTR1A BDNF-AS C2orf60 CADM2 CASC10 GAPVD1 HYAL3 IMMP2L KCNAB3 LIN7C LRRC37A2 PHC2 PIK3C2A PPM1M RHOA SUOX USP14
Number of self-reported non-cancer illnesses	2.12	1	0	0.0	0.00	1.0e+00	TDRD9
High blood pressure (siblings)	2.11	2	1	2.2	0.00	1.0e+00	FES TDRD9
Hayfever, allergic rhinitis or eczema	2.10	6	5	11.1	0.00	9.9e-01	PGAP3 RERE RP11-18I14.10 RTEL1 SUOX WBP1L
Pulse wave peak to peak time	2.10	1	0	0.0	0.00	1.0e+00	AS3MT
Leg fat-free mass (right)	2.09	19	11	24.4	0.56	6.7e-03	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 DESI1 GAPVD1 LIN7C MAP2K5 NPM1 NT5C2 PHC2 SPG7 SUOX WDR24
Leg predicted mass (right)	2.09	19	11	24.4	0.56	6.5e-03	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 DESI1 GAPVD1 LIN7C MAP2K5 NPM1 NT5C2 PHC2 SPG7 SUOX WDR24
Age started oral contraceptive pill	2.09	1	0	0.0	0.00	1.0e+00	IMMP2L
Number of incorrect matches in round	2.08	2	0	0.0	-0.06	9.4e-01	AS3MT C10orf32
Forced expiratory volume in 1-second (FEV1)	2.08	6	4	8.9	-0.26	6.2e-01	ARPC5L GAPVD1 LRRC37A2 NOB1 RHOA SUOX
Lung cancer (father)	2.08	1	0	0.0	0.00	1.0e+00	TDRD9
Whole body fat-free mass	2.08	17	11	24.4	0.54	1.5e-02	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 DESI1 GAPVD1 LIN7C NT5C2 PHC2 SPG7 SUOX WDR24
Peak expiratory flow (PEF)	2.07	6	3	6.7	-0.36	4.2e-01	ARPC5L C10orf32 GAPVD1 LRRC37A2 PPP6C TOP2B
Worry too long after embarrassment	2.07	2	0	0.0	0.00	1.0e+00	GAPVD1 LRRC37A2
Hand grip strength (right)	2.06	8	3	6.7	-0.09	8.3e-01	ACTR1A ARPC5L CADM2 GAPVD1 LRRC37A2 MAPKAP1 NOB1 NPM1
Whole body water mass	2.06	17	12	26.7	0.54	1.5e-02	ACTR1A AGBL4 ARPC5L AS3MT BAI2 BDNF-AS C10orf32 C2orf60 CADM2 DESI1 GAPVD1 LIN7C NT5C2 PHC2 SPG7 SUOX WDR24
Average weekly champagne plus white wine intake	2.04	3	0	0.0	0.00	1.0e+00	RERE SUOX WDR24
Impedance of leg (left)	2.02	21	6	13.3	-0.52	1.4e-02	ACTR1A ARPC5L AS3MT BDNF-AS CADM2 COMMD7 CPSF4 FES GAPVD1 HYAL3 KLC1 LIN7C NPM1 PHC2 PIK3C2A PPM1M PPP1R13B RHOA SEMA6D SUOX XRCC3
Qualifications: O levels/GCSEs or equivalent	2.02	1	0	0.0	0.00	1.0e+00	RHOA
Age at first live birth	2.02	2	0	0.0	0.00	1.0e+00	BAI2 WDR24
Medication for pain relief, constipation, heartburn	2.02	1	0	0.0	0.00	1.0e+00	LRRC37A2
Depression (Nagel 2018)	2.01	3	0	0.0	0.00	1.0e+00	LRRC37A2 RERE RP11-122A3.2
Neuroticism (2016)	2.01	2	0	0.0	0.00	1.0e+00	LRRC37A2 TANK
Trunk predicted mass	2.00	17	10	22.2	0.51	2.5e-02	ACTR1A AGBL4 ARPC5L AS3MT BDNF-AS C10orf32 C2orf60 CADM2 DESI1 GAPVD1 LIN7C NT5C2 PHC2 SPG7 SUOX WBP1L WDR24
Pulse rate, automated reading	2.00	6	3	6.7	-0.56	1.9e-01	CPSF4 HYAL3 MAPKAP1 MSH6 PGAP3 RHOA
Medication: Paracetamol	2.00	4	0	0.0	-0.99	1.1e-02	CASC10 COMMD7 LRRC37A2 RHOA
Lung FVC	1.99	14	10	22.2	0.05	8.6e-01	AC110781.3 CASC10 LIN7C LRRC37A2 MAP2K5 MSH6 NOB1 PDXDC2P PGAP3 RTEL1 STX1B SUOX UNC119B USP14
Chronotype (morning person)	1.99	5	0	0.0	-0.69	2.0e-01	BDNF-AS CYP2D8P1 DESI1 LIN7C TMEM161B-AS1
Trunk fat-free mass	1.99	17	10	22.2	0.52	2.4e-02	ACTR1A AGBL4 ARPC5L AS3MT BDNF-AS C10orf32 C2orf60 CADM2 DESI1 GAPVD1 LIN7C NT5C2 PHC2 SPG7 SUOX WBP1L WDR24
Body Mass Index (BMI) (2010)	1.98	3	0	0.0	0.00	1.0e+00	BDNF-AS LIN7C MAP2K5
Impedance of leg (right)	1.98	22	6	13.3	-0.68	3.5e-04	ACTR1A AS3MT BDNF-AS C2orf60 CADM2 CPSF4 FES GAPVD1 HYAL3 KLC1 LIN7C NPM1 PHC2 PIK3C2A POFUT2 PPM1M PPP1R13B RHOA SEMA6D SUOX TDRD9 XRCC3
Reaction Time	1.95	3	1	2.2	0.00	1.0e+00	AGBL4 COMMD7 RERE
Comparative body size at age 10	1.94	7	4	8.9	0.67	9.9e-02	CADM2 HYAL3 LIN7C MAP2K5 PPM1M RHOA SRR
Miserableness	1.94	6	1	2.2	0.37	4.8e-01	CELF2 CTTNBP2 LRRC37A2 RERE RHOA TANK
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.92	3	2	4.4	0.00	1.0e+00	LRRC37A2 PGAP3 TOP2B
Illnesses of father: High blood pressure	1.92	1	1	2.2	0.00	1.0e+00	FES
Mood swings	1.91	4	1	2.2	0.45	5.5e-01	CELF2 CTTNBP2 LRRC37A2 RHOA
Headache pain in last month	1.89	1	1	2.2	0.00	1.0e+00	LRRC37A2
Loneliness, isolation	1.89	2	0	0.0	0.00	1.0e+00	LRRC37A2 RERE
Mother's age at death	1.89	1	0	0.0	0.00	1.0e+00	MAPKAP1
Pulse wave Arterial Stiffness index	1.88	1	0	0.0	0.00	1.0e+00	PHC2
Frequency of depressed mood in last 2 weeks	1.87	3	0	0.0	0.00	1.0e+00	CELF2 LRRC37A2 RERE
Father's age at death	1.87	1	0	0.0	0.00	1.0e+00	FES
Hair/balding pattern: Pattern 4	1.87	3	2	4.4	0.00	1.0e+00	LRRC37A2 RERE SRR
Irritability	1.85	1	1	2.2	0.00	1.0e+00	LRRC37A2
Pulse wave reflection index	1.84	1	0	0.0	0.00	1.0e+00	HYAL3
Ever depressed for a whole week	1.83	1	0	0.0	0.00	1.0e+00	HYAL3
Alcohol drinker status: Previous	1.83	1	0	0.0	0.00	1.0e+00	XRCC3
Heart attack	1.82	2	0	0.0	0.00	1.0e+00	FES NOB1
Irritable Bowel Disease (IBD)	1.81	5	2	4.4	0.44	4.5e-01	CCDC88B FES PGAP3 RHOA RTEL1
Chronic bronchitis/emphysema (mother)	1.81	2	0	0.0	0.00	1.0e+00	MAP2K5 TOP2B
High blood pressure (mother)	1.79	1	1	2.2	0.00	1.0e+00	FES
Medication: Blood pressure	1.79	1	1	2.2	0.00	1.0e+00	FES
Taking other prescription medications	1.78	1	0	0.0	0.00	1.0e+00	CCDC88B
Forced expiratory volume in 1-second (FEV1), Best measure	1.78	5	2	4.4	-0.11	8.7e-01	ARPC5L LRRC37A2 NOB1 RHOA SUOX
Birth weight	1.78	6	2	4.4	0.33	4.7e-01	AS3MT FES LINC00899 NT5C2 SRR SUOX
Alcohol intake frequency.	1.78	7	2	4.4	-0.09	8.5e-01	CADM2 LRRC37A2 PGAP3 RP11-89K21.1 SUOX TMEM161B-AS1 WDR24
Forced vital capacity (FVC)	1.77	7	3	6.7	-0.49	2.6e-01	ARPC5L CASC10 GAPVD1 LRRC37A2 NOB1 RHOA RTEL1
Illnesses of siblings	1.77	1	0	0.0	0.00	1.0e+00	FES
Mean time to correctly identify matches	1.75	2	0	0.0	0.00	1.0e+00	AGBL4 COMMD7
Illnesses of father: Heart disease	1.75	3	1	2.2	0.00	1.0e+00	CORO1C FES LRRC37A2
Hearing difficulty/problems: Yes	1.74	1	0	0.0	0.00	1.0e+00	RP11-18I14.10
Relative age voice broke	1.74	1	1	2.2	0.00	1.0e+00	LRRC37A2
Medication: Blood pressure	1.73	1	1	2.2	0.00	1.0e+00	FES
Heart attack/myocardial infarction (self-reported)	1.73	1	0	0.0	0.00	1.0e+00	FES
Fed-up feelings	1.72	4	2	4.4	0.71	2.9e-01	CCDC88B CTTNBP2 LRRC37A2 RHOA
Coronary Artery Disease (CAD)	1.70	2	0	0.0	0.00	1.0e+00	AS3MT SPG7
Number of operations (self-reported)	1.70	3	1	2.2	0.00	1.0e+00	CASC10 HYAL3 TANK
Ulcerative Colitis (UC)	1.69	3	3	6.7	0.00	1.0e+00	PGAP3 RHOA RTEL1
Tense / 'highly strung'	1.69	2	0	0.0	0.00	1.0e+00	CADM2 RERE
Medication for cholesterol, blood pressure or diabetes	1.68	1	1	2.2	0.00	1.0e+00	FES
Number of children fathered	1.68	1	1	2.2	0.00	1.0e+00	CADM2
Crohns Disease (2012)	1.64	3	1	2.2	0.00	1.0e+00	CCDC88B PGAP3 RTEL1
Forced vital capacity (FVC), Best measure	1.64	6	3	6.7	-0.36	4.8e-01	CASC10 LRRC37A2 MSH6 NOB1 RHOA RTEL1
Neck or shoulder pain in last month	1.64	1	0	0.0	0.00	1.0e+00	SUOX
Number of treatments/medications taken	1.63	4	0	0.0	0.66	3.4e-01	CASC10 COMMD7 FES TANK
Gout (self-reported)	1.63	2	1	2.2	0.00	1.0e+00	CCDC88B NRXN2
Guilty feelings	1.62	1	0	0.0	0.00	1.0e+00	LRRC37A2
Angina (self-reported)	1.61	1	1	2.2	0.00	1.0e+00	FES
Angina	1.59	1	1	2.2	0.00	1.0e+00	FES
Frequency of tenseness / restlessness in last 2 weeks	1.59	1	1	2.2	0.00	1.0e+00	LRRC37A2
Handedness (chirality/laterality): Left-handed	1.59	1	1	2.2	0.00	1.0e+00	LRRC37A2
Pulse rate	1.57	1	0	0.0	0.00	1.0e+00	MAPKAP1
Knee pain experienced in last month	1.57	1	0	0.0	0.00	1.0e+00	AC110781.3
Number of live births	1.56	1	1	2.2	0.00	1.0e+00	CADM2
Illnesses of mother	1.55	1	1	2.2	0.00	1.0e+00	FES
Medication: Bendroflumethiazide	1.55	1	0	0.0	0.00	1.0e+00	FES
Hypothyroidism (self reported)	1.54	4	3	6.7	0.21	7.9e-01	CCDC88B RERE SUOX TANK
Number of full sisters	1.54	1	1	2.2	0.00	1.0e+00	CADM2
Heel bone mineral density (BMD) T-score, automated (left)	1.53	2	2	4.4	0.00	1.0e+00	RERE TDRD9
Hair/balding pattern: Pattern 3	1.53	1	1	2.2	0.00	1.0e+00	LRRC37A2
Crohns Disease (2017)	1.51	4	3	6.7	0.45	5.5e-01	CCDC88B FES PGAP3 RTEL1
Hair Pigment	1.50	9	6	13.3	0.01	9.8e-01	FES KLC1 MSH6 PPP1R13B RERE SPG7 SUOX TDRD9 XRCC3
Alcohol drinker status: Never	1.50	1	0	0.0	0.00	1.0e+00	CADM2
Waist Hip Ratio (WHR)	1.49	10	4	8.9	0.08	8.2e-01	ARPC5L CCDC88B GAPVD1 LRRC37A2 MAPKAP1 MSH6 PPM1M PPP6C RHOA SEMA6D
Height	1.48	33	23	51.1	-0.20	2.3e-01	ARPC5L AS3MT BTRC C10orf32 CLU COQ5 CPSF4 DESI1 DLX5 GAPVD1 HYAL3 KCNAB3 KLC1 LINC00899 LRRC37A2 MAPKAP1 NCAM1 NOB1 NT5C2 PHC2 PIK3C2A PPM1M PPP1R13B RERE RHOA RP11-122A3.2 RP11-18I14.10 SPG7 ST3GAL3 TDRD9 WBP1L WDR24 XRCC3
Standing height	1.46	23	16	35.6	-0.19	3.6e-01	ARPC5L AS3MT C10orf32 COQ5 CPSF4 DESI1 DLX5 GAPVD1 LRRC37A2 MAPKAP1 NOB1 NT5C2 PHC2 PIK3C2A PPM1M RHOA RP11-18I14.10 SPG7 TDRD9 UNC119B WBP1L WDR24 XRCC3
Heel bone mineral density (BMD) T-score, automated (right)	1.45	2	1	2.2	0.00	1.0e+00	RERE TDRD9
Blood Red Count	1.44	18	11	24.4	0.04	8.6e-01	AS3MT COMMD7 FES GTF3C6 HAX1 KCNAB3 KLC1 LRRC37A2 MAPKAP1 PGAP3 PPM1M RTEL1 SPG7 ST3GAL3 SUOX TDRD9 UNC119B XRCC3
Comparative height size at age 10	1.44	12	7	15.6	-0.45	1.2e-01	COQ5 LRRC37A2 MAPKAP1 PDE4B PIK3C2A PPM1M RP11-18I14.10 ST3GAL3 TDRD9 WBP1L WDR24 XRCC3
Medication: Amlodipine	1.42	1	1	2.2	0.00	1.0e+00	FES
Medication: Ramipril	1.40	1	0	0.0	0.00	1.0e+00	FES
Wears glasses or contact lenses	1.40	1	0	0.0	0.00	1.0e+00	CADM2
Shortness of breath walking on level ground	1.38	1	0	0.0	0.00	1.0e+00	COMMD7
Heart disease (siblings)	1.38	1	0	0.0	0.00	1.0e+00	FES
Ovarian Cancer	1.37	2	2	4.4	0.00	1.0e+00	CASC10 LRRC37A2
Medication: Allopurinol	1.37	1	1	2.2	0.00	1.0e+00	NRXN2
Hair/balding pattern: Pattern 2	1.36	1	0	0.0	0.00	1.0e+00	LRRC37A2
Forced expiratory volume in 1-second (FEV1), predicted	1.36	2	0	0.0	0.00	1.0e+00	RP11-18I14.10 WBP1L
Medication: Atenolol	1.34	1	1	2.2	0.00	1.0e+00	FES
Medication: Ventolin 100micrograms inhaler	1.34	1	1	2.2	0.00	1.0e+00	PGAP3
Sitting height	1.31	17	5	11.1	-0.19	4.4e-01	AC110781.3 ARPC5L C10orf32 CPSF4 FES GAPVD1 LRRC37A2 MAPKAP1 NCAM1 NOB1 NT5C2 PIK3C2A PPM1M RP11-18I14.10 SPG7 WBP1L WDR24
Hayfever/allergic rhinitis (self-reported)	1.30	1	0	0.0	0.00	1.0e+00	SUOX
Hypothyroidism/myxoedema (self-reported)	1.29	3	1	2.2	0.00	1.0e+00	CCDC88B SUOX TANK
Illnesses of father: None of the above (group 1)	1.27	1	1	2.2	0.00	1.0e+00	FES
Primary Biliary Cirrhosis	1.26	2	0	0.0	0.00	1.0e+00	CCDC88B PGAP3
Depression (self-reported)	1.26	1	0	0.0	0.00	1.0e+00	RERE
Blood Eosinophil Count	1.25	14	6	13.3	0.20	4.7e-01	BDNF-AS CCDC88B DESI1 KCNAB3 LIN7C LRRC37A2 MAP2K5 PGAP3 PHC2 RERE SUOX TDRD9 UNC119B XRCC3
Medication: Aspirin	1.23	1	0	0.0	0.00	1.0e+00	FES
Alzheimer’s Disease (including proxy)	1.22	2	0	0.0	0.00	1.0e+00	CLU EPHX2
Diabetes (mother)	1.22	1	0	0.0	0.00	1.0e+00	COQ5
Reason for reducing amount of alcohol drunk: Health precaution	1.22	1	0	0.0	0.00	1.0e+00	SUOX
Lung FEV1/FVC ratio	1.21	11	3	6.7	0.33	3.2e-01	ACTR1A CASC10 COMMD7 CORO1C CTTNBP2 HYAL3 LRRC37A2 MSH6 RERE SUOX TOP2B
Medication: Aspirin	1.21	1	1	2.2	0.00	1.0e+00	FES
Osteoporosis (self-reported)	1.19	1	0	0.0	0.00	1.0e+00	CCDC88B
Breast Cancer	1.17	2	1	2.2	0.00	1.0e+00	CASC10 LRRC37A2
Time employed in main current job	1.15	1	0	0.0	0.00	1.0e+00	LRRC37A2
Ever had hysterectomy (womb removed)	1.13	1	0	0.0	0.00	1.0e+00	CASC10
Mouth/teeth dental problems: Mouth ulcers	1.13	1	1	2.2	0.00	1.0e+00	LRRC37A2
HDL Cholesterol	1.11	1	1	2.2	0.00	1.0e+00	PGAP3
Medication: Levothyroxine sodium	1.11	2	1	2.2	0.00	1.0e+00	CCDC88B SUOX
Medication: Cholesterol lowering	1.08	1	1	2.2	0.00	1.0e+00	FES
Medication: Simvastatin	0.99	1	1	2.2	0.00	1.0e+00	FES
Blood Platelet Count	0.84	21	11	24.4	0.50	1.8e-02	AS3MT C10orf32 COMMD7 CORO1C CPSF4 CTD-3025N20.3 CYP2D8P1 MSH6 NT5C2 PGAP3 PHC2 PIK3C2A PPM1M RP11-18I14.10 RTEL1 SPG7 ST3GAL3 TOP2B UNC119B WBP1L WDR24

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cortex	4	0.39	2.8
GTEx	Liver	5	0.70	2.8
GTEx	Brain Frontal Cortex BA9	4	0.43	2.7
GTEx	Brain Hippocampus	3	0.57	2.7
GTEx	Brain Hypothalamus	4	0.68	2.7
GTEx	Uterus	8	1.41	2.7
GTEx	Brain Cerebellar Hemisphere	7	0.47	2.6
GTEx	Brain Cerebellum	11	0.55	2.6
GTEx	Brain Nucleus accumbens basal ganglia	5	0.58	2.6
GTEx	Cells EBV-transformed lymphocytes	11	0.77	2.6
GTEx	Heart Left Ventricle	9	0.59	2.6
GTEx	Muscle Skeletal	18	0.62	2.6
GTEx	Ovary	9	0.99	2.6
GTEx	Pituitary	5	0.45	2.6
GTEx	Prostate	5	0.60	2.6
GTEx	Small Intestine Terminal Ileum	1	0.22	2.6
The Cancer Genome Atlas	Glioblastoma Multiforme	9	0.88	2.6
GTEx	Adipose Subcutaneous	27	0.77	2.5
GTEx	Adipose Visceral Omentum	12	0.59	2.5
GTEx	Artery Coronary	8	0.68	2.5
GTEx	Brain Caudate basal ganglia	4	0.43	2.5
GTEx	Breast Mammary Tissue	13	0.66	2.5
GTEx	Cells Transformed fibroblasts	23	0.55	2.5
GTEx	Esophagus Muscularis	12	0.37	2.5
GTEx	Heart Atrial Appendage	9	0.57	2.5
GTEx	Lung	14	0.49	2.5
GTEx	Pancreas	8	0.49	2.5
GTEx	Skin Not Sun Exposed Suprapubic	13	0.53	2.5
GTEx	Skin Sun Exposed Lower leg	22	0.60	2.5
GTEx	Spleen	5	0.35	2.5
GTEx	Stomach	8	0.55	2.5
GTEx	Thyroid	19	0.48	2.5
GTEx	Whole Blood	12	0.60	2.5
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.29	2.5
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	7	0.44	2.5
GTEx	Adrenal Gland	4	0.27	2.4
GTEx	Artery Aorta	17	0.57	2.4
GTEx	Artery Tibial	23	0.61	2.4
GTEx	Brain Putamen basal ganglia	4	0.64	2.4
GTEx	Breast Mammary Tissue (Female)	11	0.67	2.4
GTEx	Colon Sigmoid	9	0.62	2.4
GTEx	Colon Transverse	8	0.39	2.4
GTEx	Esophagus Gastroesophageal Junction	10	0.69	2.4
GTEx	Esophagus Mucosa	13	0.39	2.4
GTEx	Nerve Tibial	20	0.46	2.4
GTEx	Testis	11	0.35	2.4
METSIM	Adipose	23	0.50	2.4
ROSMAP	Brain Pre-frontal Cortex	17	0.39	2.4
CommonMind	Brain Pre-frontal Cortex	20	0.37	2.4
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	6	0.54	2.4
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	7	0.63	2.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	7	0.53	2.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	6	0.56	2.4
GTEx	Breast Mammary Tissue (Male)	4	0.34	2.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	19	0.43	2.3
The Cancer Genome Atlas	Colon Adenocarcinoma	13	0.63	2.3
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	11	0.40	2.3
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	14	0.34	2.3
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.44	2.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	11	0.26	2.3
The Cancer Genome Atlas	Lung Adenocarcinoma	13	0.44	2.3
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	10	0.40	2.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	4	0.57	2.3
The Cancer Genome Atlas	Skin Cutaneous Melanoma	2	0.37	2.3
The Cancer Genome Atlas	Stomach Adenocarcinoma	3	0.18	2.3
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.16	2.3
The Cancer Genome Atlas	Thyroid Carcinoma	17	0.33	2.3
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.20	2.3
GTEx	Vagina	2	0.31	2.2
NTR	Blood	13	0.54	2.2
YFS	Blood	13	0.28	2.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	5	0.30	2.2
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	6	0.36	2.2
The Cancer Genome Atlas	Prostate Adenocarcinoma	18	0.39	2.2